Janux Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Janux Therapeutics, Inc. (JANX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$24.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- Janux Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$506.00K.
- Janux Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$356.86M, a 284.33% decline year-over-year.
- Janux Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $193.60M.
- Janux Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$21.07M, a 207.80% decline year-over-year.
- Janux Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$378.27M, a 191.95% decline from fiscal 2024.
- Janux Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $411.40M.
- Janux Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$32.22M, a 303.36% decline from fiscal 2022.
- Janux Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $15.84M, a 44.57% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$24.57M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$506.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$378.27M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$382.22M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$378.16M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$356.86M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $411.40M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $7.55M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$4.54M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $193.60M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$32.22M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | -$34.27M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | -$17.72M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | -$21.07M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $15.84M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $29.17M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $22.82M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $19.55M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $28.59M 10-K · filed 2023-03-10 | |||
| 2021-09-30 | $31.58M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $243.81M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $62.96M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $7.16M 10-K · filed 2022-03-18 | |||
| 2020-09-30 | $4.23M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $5.35M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |